NovaBridge Biosciences

NBP Healthcare Biotechnology

In the quarter to June 2026, EPS fell 123.3% and free cash flow grew 34.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

1.26 0.03 −2.33%
Market cap
$149.6M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
n/a
Altman Z
−3.80
Beneish M
n/a
Dividend safety
n/a
Older periods Mar '25 Jun '25 Sep '25 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
22.35 22.82 14.47 7.64
Net Debt/EBITDA
32.02 23.28 0.00 0.00
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
0.00 (0.10) 0.00 0.00
Book value per Share
2.52 2.41 0.00 0.00
Free Cash Flow
— (7.79) 1.84 (32.93)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 1 Oct 2026